A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)
Condition: Triple-Negative Breast Cancer Intervention: Drug: camrelizumab in combination with nab-paclitaxel and famitinib Sponsor: Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials